This site is intended for healthcare professionals
News

CHMP recommends Lynparza for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient -positive advanced ovarian cancer. AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:16th Mar 2021
Published:22nd Sep 2020
Condition: Ovarian Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest